Article Link: FDA Approves Lenvima (lenvatinib) for First-line Treatment of Unresectable Hepatocellular Carcinoma (HCC) Woodcliff Lake, N...
FDA Approves Kalydeco (ivacaftor) for Cystic Fibrosis in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene
Article Link: FDA Approves Kalydeco (ivacaftor) for Cystic Fibrosis in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene&#...
FDA Approves Galafold (migalastat) for the Treatment of Fabry Disease
Article Link: FDA Approves Galafold (migalastat) for the Treatment of Fabry Disease August 10, 2018 — The U.S. Food and Drug Admini...
FDA Approves Annovera (segesterone acetate and ethinyl estradiol) Vaginal Contraceptive System
Article Link: FDA Approves Annovera (segesterone acetate and ethinyl estradiol) Vaginal Contraceptive System NEW YORK, Aug. 10, 2018 /PRN...
FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR
Article Link: FDA Approves Onpattro (patisiran) Targeted RNA-based Therapy for Polyneuropathy Caused by hATTR August 10, 2018 — The...
FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD)
Article Link: FDA Approves Jornay PM (methylphenidate) Extended-Release Capsules for Attention Deficit Hyperactivity Disorder (ADHD) GEOR...
FDA Approves Arakoda (tafenoquine) for the Prevention of Malaria
Article Link: FDA Approves Arakoda (tafenoquine) for the Prevention of Malaria WASHINGTON, Aug. 9, 2018 /PRNewswire/ — 60 Degrees P...
FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis
Article Link: FDA Approves Orilissa (elagolix) for the Management of Moderate to Severe Pain Associated with Endometriosis NORTH CHICAGO,...
FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria
Article Link: FDA Approves Krintafel (tafenoquine) for the Radical Cure of Plasmodium vivax Malaria London UK; Philadelphia US; Geneva, S...
FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen
Article Link: FDA Approves Nivestym (filgrastim-aafi), a Biosimilar to Neupogen July 20, 2018 – Pfizer Inc. (NYSE:PFE) today announ...
